WO1998051788A3 - Method and construct for inhibition of cell migration - Google Patents

Method and construct for inhibition of cell migration Download PDF

Info

Publication number
WO1998051788A3
WO1998051788A3 PCT/NL1998/000259 NL9800259W WO9851788A3 WO 1998051788 A3 WO1998051788 A3 WO 1998051788A3 NL 9800259 W NL9800259 W NL 9800259W WO 9851788 A3 WO9851788 A3 WO 9851788A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
domain
protein
hybrid polypeptide
acid molecule
Prior art date
Application number
PCT/NL1998/000259
Other languages
French (fr)
Other versions
WO1998051788A2 (en
Inventor
Paulus Hubertus Andreas Quax
Johan Hendrikus Verheijen
Original Assignee
Tno
Paulus Hubertus Andreas Quax
Johan Hendrikus Verheijen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tno, Paulus Hubertus Andreas Quax, Johan Hendrikus Verheijen filed Critical Tno
Priority to EP98923197A priority Critical patent/EP0981606A2/en
Priority to NZ500656A priority patent/NZ500656A/en
Priority to CA002289117A priority patent/CA2289117A1/en
Priority to AU75536/98A priority patent/AU7553698A/en
Priority to JP54907798A priority patent/JP2001525669A/en
Publication of WO1998051788A2 publication Critical patent/WO1998051788A2/en
Publication of WO1998051788A3 publication Critical patent/WO1998051788A3/en
Priority to NO995564A priority patent/NO995564L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A recombinant nucleic acid molecule comprising a vector useful for transfection or transduction of mammalian cells, wherein said vector contains a nucleic acid insertion encoding an expressible hybrid polypeptide or protein which comprises a domain with a binding function and a domain with an effector function. The domain with a binding function may comprise a receptor binding domain, and the domain with an effector function may have enzymatic activity, in particular protease inhibitor activity. The vector may be a viral (e.g. adenovirus or retrovirus) or non-viral vector useful for transfection or transduction of mammalian cells. The nucleic acid insertion encoding an expressible hybrid polypeptide or protein may be under the control of a cell- or tissue-specific promoter. A process for preventing local proteolytic activity, extracellular matrix degradation, cell migration, cell invasion, or tissue remodeling, comprising transfecting or transducing the cells involved or cells in their environment with the recombinant nucleic acid molecule to obtain local expression of the hybrid polypeptide or protein encoded thereby. A process for producing the hybrid polypeptide or protein by transfecting or transducing mammalian cells with the recombinant nucleic acid molecule to obtain expression and optionally recovering the hybrid polypeptide or protein produced.
PCT/NL1998/000259 1997-05-12 1998-05-11 Method and construct for inhibition of cell migration WO1998051788A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP98923197A EP0981606A2 (en) 1997-05-12 1998-05-11 Method and construct for inhibition of cell migration
NZ500656A NZ500656A (en) 1997-05-12 1998-05-11 Vector containing a nucleic acid insertion expressing a hybrid polypeptide with a protease inhibitor domain and a receptor binding domain
CA002289117A CA2289117A1 (en) 1997-05-12 1998-05-11 Method and construct for inhibition of cell migration
AU75536/98A AU7553698A (en) 1997-05-12 1998-05-11 Method and construct for inhibition of cell migration
JP54907798A JP2001525669A (en) 1997-05-12 1998-05-11 Methods and constructs for inhibiting cell migration
NO995564A NO995564L (en) 1997-05-12 1999-11-12 Method and construction for cell migration inhibition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97201423.7 1997-05-12
EP97201423 1997-05-12

Publications (2)

Publication Number Publication Date
WO1998051788A2 WO1998051788A2 (en) 1998-11-19
WO1998051788A3 true WO1998051788A3 (en) 1999-05-20

Family

ID=8228315

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL1998/000259 WO1998051788A2 (en) 1997-05-12 1998-05-11 Method and construct for inhibition of cell migration

Country Status (7)

Country Link
EP (1) EP0981606A2 (en)
JP (1) JP2001525669A (en)
AU (1) AU7553698A (en)
CA (1) CA2289117A1 (en)
NO (1) NO995564L (en)
NZ (1) NZ500656A (en)
WO (1) WO1998051788A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055365A1 (en) 1998-04-30 1999-11-04 Cornell Research Foundation, Inc. Adenoviral vectors with tandem fiber proteins
AU767975B2 (en) 1998-09-11 2003-11-27 Genvec, Inc. Alternatively targeted adenovirus
DE10020125A1 (en) * 2000-04-18 2001-10-25 Friedrich Schiller Uni Jena Bu Agent for stimulating bone regrowth, useful as insert after surgery for bone cancer, comprises single sequence expressing a fusion of growth factor and protease inhibitor
EP1903113A1 (en) * 2000-12-18 2008-03-26 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
US7247704B2 (en) 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
CA2430973A1 (en) * 2000-12-18 2002-06-27 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
PT1436397E (en) * 2001-10-11 2010-07-15 Angeletti P Ist Richerche Bio Hepatitis c virus vaccine
CA2461380C (en) 2001-10-11 2011-03-22 Merck & Co., Inc. Hepatitis c virus vaccine

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988009344A1 (en) * 1987-05-21 1988-12-01 Creative Biomolecules, Inc. Targeted multifunctional proteins
EP0383599A2 (en) * 1989-02-17 1990-08-22 Merck & Co. Inc. Protein anti-cancer agent
EP0404750A1 (en) * 1989-05-26 1990-12-27 Washington University Tissue inhibitor of metalloproteases (TIMP-2)
EP0439954A2 (en) * 1989-12-22 1991-08-07 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
WO1991012328A1 (en) * 1990-02-15 1991-08-22 Fowlkes Dana M Totally synthetic affinity reagents
WO1992002553A1 (en) * 1990-08-03 1992-02-20 Delta Biotechnology Limited Tumor cell binding molecule with protease inhibiting region
EP0623676A1 (en) * 1989-05-19 1994-11-09 Amgen Inc. Metalloproteinase inhibitor
WO1995011987A1 (en) * 1993-10-29 1995-05-04 Incyte Pharmaceuticals, Inc. Chimeric proteins including protease nexin-1 variants
WO1995013091A1 (en) * 1993-11-12 1995-05-18 International Technology Management Associates, Ltd. Methods of repairing connective tissues
WO1995017885A1 (en) * 1993-12-27 1995-07-06 Rutgers, The State University Of New Jersey Inhibitors of urokinase plasminogen activator
WO1995021601A2 (en) * 1994-01-11 1995-08-17 Protein Engineering Corporation Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof
WO1995028955A1 (en) * 1994-04-22 1995-11-02 Gliemann Joergen PEPTIDES BINDING TO THE α2-MACROGLOBULIN RECEPTOR/LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN
US5504001A (en) * 1987-11-25 1996-04-02 Zymogenetics, Inc. Hybrid plasminogen activator
WO1996023814A1 (en) * 1995-02-03 1996-08-08 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
WO1996034009A1 (en) * 1995-04-27 1996-10-31 Rutgers, The State University Of New Jersey Chimeric nucleic acids and proteins for inhibiting hiv-1 expression
WO1997000949A1 (en) * 1995-06-20 1997-01-09 Massachusetts Institute Of Technology Z-dna binding protein and applications
WO1997025422A1 (en) * 1996-01-08 1997-07-17 Nissin Food Products Co., Ltd. Cancerous metastasis inhibitor

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988009344A1 (en) * 1987-05-21 1988-12-01 Creative Biomolecules, Inc. Targeted multifunctional proteins
US5504001A (en) * 1987-11-25 1996-04-02 Zymogenetics, Inc. Hybrid plasminogen activator
EP0383599A2 (en) * 1989-02-17 1990-08-22 Merck & Co. Inc. Protein anti-cancer agent
EP0623676A1 (en) * 1989-05-19 1994-11-09 Amgen Inc. Metalloproteinase inhibitor
EP0404750A1 (en) * 1989-05-26 1990-12-27 Washington University Tissue inhibitor of metalloproteases (TIMP-2)
EP0439954A2 (en) * 1989-12-22 1991-08-07 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
WO1991012328A1 (en) * 1990-02-15 1991-08-22 Fowlkes Dana M Totally synthetic affinity reagents
WO1992002553A1 (en) * 1990-08-03 1992-02-20 Delta Biotechnology Limited Tumor cell binding molecule with protease inhibiting region
WO1995011987A1 (en) * 1993-10-29 1995-05-04 Incyte Pharmaceuticals, Inc. Chimeric proteins including protease nexin-1 variants
WO1995013091A1 (en) * 1993-11-12 1995-05-18 International Technology Management Associates, Ltd. Methods of repairing connective tissues
WO1995017885A1 (en) * 1993-12-27 1995-07-06 Rutgers, The State University Of New Jersey Inhibitors of urokinase plasminogen activator
WO1995021601A2 (en) * 1994-01-11 1995-08-17 Protein Engineering Corporation Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof
WO1995028955A1 (en) * 1994-04-22 1995-11-02 Gliemann Joergen PEPTIDES BINDING TO THE α2-MACROGLOBULIN RECEPTOR/LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN
WO1996023814A1 (en) * 1995-02-03 1996-08-08 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
WO1996034009A1 (en) * 1995-04-27 1996-10-31 Rutgers, The State University Of New Jersey Chimeric nucleic acids and proteins for inhibiting hiv-1 expression
WO1997000949A1 (en) * 1995-06-20 1997-01-09 Massachusetts Institute Of Technology Z-dna binding protein and applications
WO1997025422A1 (en) * 1996-01-08 1997-07-17 Nissin Food Products Co., Ltd. Cancerous metastasis inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
QUAX P H A ET AL: "Inhibition of neointima formation in cultured human saphenous vein segments by an adenovirus expressing an urokinase receptor binding plasmin inhibitor", CIRCULATION, vol. 96, no. 8-Suppl., 21 October 1997 (1997-10-21), us, pages I669, XP002084540 *

Also Published As

Publication number Publication date
NO995564L (en) 2000-01-11
NZ500656A (en) 2001-11-30
WO1998051788A2 (en) 1998-11-19
JP2001525669A (en) 2001-12-11
CA2289117A1 (en) 1998-11-19
EP0981606A2 (en) 2000-03-01
AU7553698A (en) 1998-12-08
NO995564D0 (en) 1999-11-12

Similar Documents

Publication Publication Date Title
CA2136441A1 (en) Adeno-associated virus with inverted terminal repeat sequences as promoter
WO1998056927A3 (en) Nucleic acids encoding polypeptide having protease activity
CA2311643A1 (en) Compositions and methods for inducing gene expression
WO1998045456A8 (en) 2-deoxyglucose-6-phosphate (2-dog-6-p) phosphatase dna sequences as selection markers in plants
CA2672809A1 (en) Vector for expressing recombinant protein and cho cells transfected with same
EP1798239A3 (en) G-protein coupled receptors and uses therefor
MX9709549A (en) Recombinant adenoviruses, use thereof for preparing aavs, complementary cell line, and pharmaceutical compositions containing said adenoviruses.
AU7599500A (en) Novel gl50 molecules and uses therefor
CA2245006A1 (en) Protein expression system
KR960010864A (en) Recombinant DNA Virus Vectors for Transfection of Animal Cells
WO1998022574A3 (en) Type i recombinant clostridium histolyticum collagenase and its use for isolating cells and cell aggregates
DK1222298T3 (en) Vectors and methods for recombinant protein expression
WO1999067398A3 (en) Overexpression of phytase genes in yeast systems
IE831211L (en) Cloning vectors for expression of exogenous protein
ATE450603T1 (en) POLYPEPTIDES WITH BRANCHING ENZYME ACTIVITY AND NUCLEIC ACIDS ENCODING THEM
WO1998051788A3 (en) Method and construct for inhibition of cell migration
EP0889133A3 (en) Process for producing microbial transglutaminase
WO1999021976A3 (en) Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
AU3802595A (en) Tripeptidyl aminopeptidase
CA2252493A1 (en) .beta.-galactoside - .alpha. 2,6-sialyltransferase gene
WO2000052136A3 (en) Human glycosylation enzymes
WO2005065348A3 (en) Transactivation system for mammalian cells
NZ502450A (en) Recombinant expression of multimeric polypeptide comprising multiple copies of insulin c-peptide
WO2001094383A3 (en) Mutated furin polypeptides having improved characteristics
ATE288488T1 (en) COMPOSITIONS AND METHODS FOR ELIMINATING UNDESIRABLE CELLS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1998923197

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 500656

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2289117

Country of ref document: CA

Ref country code: CA

Ref document number: 2289117

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 549077

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 75536/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 09423838

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998923197

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1998923197

Country of ref document: EP